Clinical features and para-clinical findings of cryptococcal meningitis in the North of Iran during 2011-19

Document Type : Original Articles


1 Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

3 Invasive Fungi Research Center, communicable diseaes institue,Mazandaran University of Medical Sciences, Sari, Iran.

4 Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran



Background and Purpose:Cryptococcalmeningitis (CM) is a serious fungal infection that especially affectspatients with human immunodeficiency virus (HIV). In this regard,the presentretrospective study aimed to analyze the clinical and laboratory features and therapeutic outcomes of patients with CM admitted totwo teaching referral centersin the north of Iran during 2011-19.
Materials and Methods:This studywas performed onall the hospitalized patients diagnosedwith CM in two therapeutic centers of infectious diseases in the north of Iran. The required data,such as demographic characteristicsandclinical and paraclinical featuresof patients,were extracted and entered in the information forms. Finally, the collected data were analyzed inSPSSsoftware(version16).
Results:For the purpose of the study, records of 12confirmed CM patients were evaluatedin this research. Based onthe results,75% ofthepatients were male.Moreover,the average age of the subjectswas 40.33± 8.93 years oldand 66.6%ofthem(n=8) were HIV-positive. Other underlying diseases among HIV-positive patients includedinfection with hepatitis C virus (25%) and a history of tuberculosis (25%). In total, threeHIV-negative patients suffered from Hodgkin lymphoma (25%), sarcoidosis (25%),and asthma (25%) and one patient (25%) had no underlying disease. Headache (75%), weakness,and fatigue (75%) were the most common symptomsamong the participants. The cluster of differentiation 4count in all HIV-positive patients was less than 100 cells/μl. There was no significant difference between symptoms in HIV-positive and HIV-negative patients. Besides, no significant differencewas observedbetween the groups of HIV-positive and HIV-negative patientsregardingthe period betweentheonset of symptoms and diagnosisof CM,the length of hospital stay,and the duration of antifungal medicationconsumption. In total,threepatients (25%) expired,and six patients recovered. The CM recurred in two HIV-negative and oneHIV-positivesubjects;the two HIV-negativepatientswere treated,whilethe HIV-positivepatientexpired due to thisrecurrence.
Conclusion:Clinical features and cerebrospinal fluid parameters were not different in HIV-positive and HIV-negative participants. Despite the fact thatCM is not commoninIran, due to the increasing number of immunosuppressive patients, the differential diagnosis of CM should be considered forpatients with signs and symptoms of infection in the central nervous system.


1. Badali H, Alian S, Fakhim H, Falahatinejad M, Moradi A, Mohammad Davoudi M, et al. Cryptococcal meningitis due to Cryptococcus neoformans genotype AFLP1/VNI in Iran: a review of the literature. Mycoses. 2015; 58(12):689-93.
2. Bandalizadeh Z, Seyedmousavi M, Melchers WJ, Fami Zaghrami M, Mostaed Rostami AA, Shokohi T. Cryptococcus and cryptococcosis: updates on pathogenesis, diagnosis and treatment strategies for HIV infected patients. J Mazandaran Univ Med Sci. 2018; 28(163):144-72.
3. Rezai MS, Khotael G, Kheirkhah M, Hedayat T, Geramishoar M, Mahjoub F. Cryptococcosis and deficiency of interleukin12r. Pediatr Infect Dis J. 2008; 27(7):673.
4. Pakshir K, Fakhim H, Vaezi A, Meis JF, Mahmoodi M, Zomorodian K, et al. Molecular epidemiology of environmental Cryptococcus species isolates based on amplified fragment length polymorphism. J Mycol Med. 2018; 28(4):599-605.
5. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46(11):1694-701.
6. Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep. 2015; 2(2):90-9.
7. Bandalizadeh Z, Shokohi T, Badali H, Abastabar M, Babamahmoudi F, Davoodi L, et al. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex. J Med Microbiol. 2020; 69(1):72-81.
8. Pescador MR, Thapa B. Meningitis, cryptococcal. Treasure Island (FL): StatPearls Publishing; 2020.
9. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2005; 72(1):99-118.
10. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8.
11. Hedayati MT, Taghizadeh Armaki M, Yazdani Charati J, Hedayati N, Seyedmousavi S, Denning DW. Burden of fungal infections in Iran. Journal of infection in developing countries. 2018; 12(10):910-8.
12. Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2011; 44(5):338-45.
13. Ghasemian R, Najafi N, Shokohi T. Cryptococcal meningitis relapse in an immunocompetent patient. Arch Clin Infect Dis. 2011; 6(1):51-5.
14. Liao CH, Chi CY, Wang YJ, Tseng SW, Chou CH, Ho CM, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. J Microbiol Immunol Infect. 2012; 45(4):296-304.
15. Zhang C, Tan Z, Tian F. Impaired consciousness and decreased glucose concentration of CSF as prognostic factors in immunocompetent patients with cryptococcal meningitis. BMC Infect Dis. 2020; 20(1):69.
16. Liu Y, Kang M, Wu SY, Ma Y, Chen ZX, Xie Y, et al. Different characteristics of cryptococcal meningitis between HIV-infected and HIV-uninfected patients in the Southwest of China. Med Mycol. 2017; 55(3):255-61.
17. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50(3):291-322.
Volume 6, Issue 4
December 2020
Pages 41-46
  • Receive Date: 01 September 2020
  • Revise Date: 12 November 2020
  • Accept Date: 12 November 2020
  • First Publish Date: 22 November 2020